Shares of Hims & Hers Health (NYSE:HIMS) climbed ~34% in the premarket on Tuesday after the telehealth company announced a ...

TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943, is an innovative triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Medicare coverage of obesity medications could drive a substantial rise in healthcare spending, according to a new study. A microsimulation model published in JAMA Health Forum projected that Medicare ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Fridays weight loss is a telehealth provider that offers access to popular GLP-1 medications, including compounded versions ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

All these drugs are very effective and they’ve become a game changer for people who need to lose weight. Get on the drug, eat ...

Researchers at the Pennington Biomedical Research Center have found new clues about how the drug tirzepatide, also known by ...

With age comes wisdom. But you know what else can come with age? Weight gain. Losing weight can also be harder as you grow ...

The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.